Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| 10264 | ETCTN | The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10266 | ETCTN | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10268 | ETCTN | Randomized Phase II Trial of Topotecan plus M6620 (VX-970) vs. Topotecan alone in Patients with Relapsed Small-Cell Lung Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10272 | NCORP-National Institutes of Health | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| 10273 | ETCTN | A Phase 1 Study of M3814 in combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10276 | ETCTN | A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10285 | ETCTN | Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10287 | ETCTN | A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA) | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10291 | ETCTN | A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 10292 | ETCTN | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |